ClinicalTrials.gg
CompletedNCT01449812Updated Jun 6, 2018Results posted

Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine

A Phase 3 interventional study of Infanrix+Hib™ and Poliorix™ in Acellular Pertussis, Tetanus and Diphtheria, sponsored by GlaxoSmithKline. Completed at 2 sites in China. Open to participants aged 18 Months to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
831
Allocation
Randomized
Ages
18 Months to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Tetanus by GlaxoSmithKline — none open to participants now, 1 under way, 1 of them phase 3. Tetanus · GlaxoSmithKline.

Enrollment
15th of 98
831 · median 444
Started
2011
with 6 others
Phase 3
60 of 106
none open now
Registered
77th of 106
by date

Among the 106 studies in Tetanus by GlaxoSmithKline, this one is the 15th largest by enrollment of the 98 interventional ones that give a count, is one of 7 that started in 2011, is one of 60 in phase 3, and was the 77th registered.

Tetanus

319 studies on the registry are indexed under Tetanus; 30 are open to participants now.

Browse Tetanus studies →

Open to participants now

None of the 106 studies in Tetanus by GlaxoSmithKline is open now. The open studies under Tetanus, anywhere →

Who these studies take

Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Months to 24 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 106 studies in Tetanus by GlaxoSmithKline as a file.
02

Study summary

The purpose of this booster study is to evaluate the immune persistence in healthy Chinese subjects primed in study NCT01086423 with GSK Biologicals' Infanrix-IPV+Hib™ (DTPa-IPV/Hib) vaccine. The study will also evaluate the safety and immune response of these subjects to a booster dose of Infanrix-Hib™ (DTPa/Hib) and Poliorix™ (IPV) vaccine.

This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT01086423).

03

Conditions studied

  • Acellular Pertussis
  • Tetanus
  • Diphtheria
  • Haemophilus Influenzae Type b

Keywords

  • combination vaccine
  • booster vaccination
04

Who can participate

Ages eligible
18 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female child between, and including, 18 and 24 months of age at the time of the booster vaccination.
  • Subjects who completed the full three-dose primary vaccination course in study NCT01086423.
  • Subjects who the investigator believes that their parent(s)/ Legally Acceptable Representative(s) LAR(s) can and will comply with the requirements of the protocol
  • Written obtained from the parent(s)/LAR(s) of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Child in care
  • Use of any or non-registered product other than the study vaccine(s) within 30 days preceding the booster dose of the study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs within six months prior to the booster dose.
  • Administration of a vaccine not foreseen by the study protocol within 30 days prior to the booster vaccination, or planned administration during the study period.
  • Participation in another clinical study within three months prior to enrolment in the present booster study or at any time during the present booster study, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Evidence of previous diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b, vaccination or disease since the conclusion visit of primary study NCT01086423.
  • Serious chronic illness.
  • Administration of immunoglobulins and/or any blood products within the 90 days preceding the booster dose of study vaccine or planned administration during the study period.
  • Occurrence of any of the following adverse events after a previous administration of a DTP vaccine.
  • Encephalopathy
  • Temperature of ≥ 40.0°C (axillary temperature) within 48 hours of vaccination, not due to another identifiable cause.
  • Collapse or shock-like state within 48 hours of vaccination.
  • Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting ≥ 3 hours.
  • Seizures with or without fever occurring within 3 days of vaccination.

The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:

  • Acute disease and/or fever at the time of enrolment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
831 participants (actual)

Study arms

  • Experimental
    INFANRIX+HIB/POLIORIX 1 GROUP

    Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.

    Biological: Infanrix+Hib™ · Biological: Poliorix™

  • Experimental
    INFANRIX+HIB/POLIORIX 2 GROUP

    Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.

    Biological: Infanrix+Hib™ · Biological: Poliorix™

  • Active comparator
    CONTROL GROUP

    Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix+Hib™ and of Poliorix™ vaccines at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.

    Biological: Infanrix+Hib™ · Biological: Poliorix™

Interventions

  • BiologicalInfanrix+Hib™

    Intramuscular, one dose

    Also known as: DTPa /Hib

  • BiologicalPoliorix™

    Intramuscular, one dose

    Also known as: IPV

06

What researchers measure

Primary outcomes

  1. Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids

    A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).

    Time frame: Before the booster vaccination (At Day 0)

  2. Anti-D and Anti-T Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥0.1 IU/mL.

    Time frame: Before the booster vaccination (At Day 0)

  3. Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (Anti-PRP)

    A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL).

    Time frame: Before the booster vaccination (At Day 0)

  4. Anti-PRP Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 µg/mL.

    Time frame: Before the booster vaccination (At Day 0)

  5. Number of Seroprotected Subjects Against Polio Type 1, 2 and 3

    A seroprotected subject was defined as a vaccinated subject with anti-polio type 1, 2 and 3 antibody concentrations ≥ the cut-off value of 8 Estimated Dose 50% (ED50). ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.

    Time frame: Before the booster vaccination (At Day 0)

  6. Anti-polio Type 1, 2 and 3 Antibody Titers

    Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ 8.

    Time frame: Before the booster vaccination (At Day 0)

  7. Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)

    A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentration ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/ml).

    Time frame: Before the booster vaccination (At Day 0)

  8. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.

    Time frame: Before the booster vaccination (At Day 0)

  9. Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoids

    A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 IU/mL.

    Time frame: Before the booster vaccination (At Day 0)

  10. Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoids

    A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  11. Anti-D and Anti-T Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.1 IU/mL.

    Time frame: Before the booster vaccination (At Day 0)

  12. Anti-D and Anti-T Antibody Concentrations

    Antibody concentrations were presented as GMCs for the seroprotection cut-off of ≥ 0.1 IU/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  13. Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)

    A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentration ≥ 0.15 µg/mL.

    Time frame: Before the booster vaccination (At Day 0)

  14. Number of Seroprotected Subjects Against PRP

    A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentrations ≥ 0.15 µg/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  15. Anti-PRP Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 micrograms per milliliter (µg/mL).

    Time frame: Before the booster vaccination (At Day 0)

  16. Anti-PRP Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 µg/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  17. Number of Seroprotected Subjects for Anti-polio Type 1, 2 and 3

    A seroprotected subject was defined as a vaccinated subject with anti-polivirus antibody concentration ≥ 8 ED50. ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.

    Time frame: Before the booster vaccination (At Day 0)

  18. Number of Seroprotected Subjects Against Polio Type 1, 2 and 3

    A seroprotected subject was defined as a vaccinated subject with anti-polivirus antibody concentrations ≥ 8 ED50. ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.

    Time frame: One month after the booster vaccination (At Month 1)

  19. Anti-polio Type 1, 2 and 3 Antibody Titers

    Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ the value of 8.

    Time frame: Before the booster vaccination (At Day 0)

  20. Anti-polio Type 1, 2 and 3 Antibody Titers

    Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ 8.

    Time frame: One month after the booster vaccination (At Month 1)

  21. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN

    A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 ELISA units per milliliter (EL.U/mL).

    Time frame: Before the booster vaccination (At Day 0)

  22. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN

    A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  23. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

    Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off value of ≥ 5 EL.U/mL.

    Time frame: Before the booster vaccination (At Day 0)

  24. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrattions

    Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.

    Time frame: One month after the booster vaccination (At Month 1)

  25. Number of Subjects With a Booster Response to Anti-PT, Anti-FHA and Anti-PRN

    Booster response was defined as the appearance of antibodies in subjects who were initially seronegative (i.e. with concentrations \< cut-off value) or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e. with concentrations ≥ cut-off value), taking into consideration the decreasing maternal antibodies.

    Time frame: One month after the booster vaccination (At Month 1)

Secondary outcomes

  1. Number of Subjects With Any Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: During the 4-day (Days 0-3) post-vaccination period

  2. Number of Subjects With Any Solicited General Symptoms

    Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever \[defined as axillary temperature equal to or above 37.1 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade and relationship to vaccination.

    Time frame: During the 4-day (Days 0-3) post-vaccination period

  3. Number of Subjects With Any Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During the 31-day (Days 0-30) post-vaccination period

  4. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: During the entire study period (from Month 0 up to Month 1)

07

Results

Posted Apr 13, 2017

Participant flow

6 subjects did not receive vaccination.

Participant flow — Overall Study
MilestoneInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Started272273280
Completed270273279
Not completed201
Withdrew: Migrated/moved from study area100
Withdrew: Withdrawal by subject001
Withdrew: Lost to follow-up100

Outcome measures

PrimaryNumber of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids

A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-D241250234
Anti-T269271275
PrimaryAnti-D and Anti-T Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥0.1 IU/mL.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Geometric mean · IU/mL
Anti-D and Anti-T Antibody Concentrations
IU/mLInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-D0.175 (0.163 to 0.188)0.189 (0.176 to 0.202)0.154 (0.142 to 0.166)
Anti-T0.45 (0.423 to 0.478)0.509 (0.481 to 0.54)0.38 (0.359 to 0.404)
PrimaryNumber of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (Anti-PRP)

A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL).

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (Anti-PRP)
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (Anti-PRP)226234241
PrimaryAnti-PRP Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 µg/mL.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-PRP Antibody Concentrations2.275 (1.856 to 2.788)2.674 (2.193 to 3.26)2.413 (2.006 to 2.904)
PrimaryNumber of Seroprotected Subjects Against Polio Type 1, 2 and 3

A seroprotected subject was defined as a vaccinated subject with anti-polio type 1, 2 and 3 antibody concentrations ≥ the cut-off value of 8 Estimated Dose 50% (ED50). ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Polio Type 1, 2 and 3
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-polio 1259267270
Anti-polio 2248261250
Anti-polio 3254259257
PrimaryAnti-polio Type 1, 2 and 3 Antibody Titers

Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ 8.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Geometric mean · Titers
Anti-polio Type 1, 2 and 3 Antibody Titers
TitersInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-polio 172.3 (62.4 to 83.7)95.7 (82.5 to 111)77.2 (67 to 89)
Anti-polio 257.3 (47 to 70)63.6 (53.5 to 75.5)42.6 (35.7 to 50.8)
Anti-polio 371.3 (60.1 to 84.7)79.9 (66.4 to 96.2)60.6 (51.2 to 71.8)
PrimaryNumber of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)

A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentration ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/ml).

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-PT260263260
Anti-FHA262267262
Anti-PRN260265267
PrimaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
EL.U/mLInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-PT10.3 (9.6 to 11.1)12.2 (11.3 to 13.1)10.4 (9.6 to 11.2)
Anti-FHA12.8 (11.9 to 13.7)14.3 (13.4 to 15.2)12.4 (11.5 to 13.4)
Anti-PRN9.2 (8.8 to 9.7)9.7 (9.2 to 10.1)9 (8.5 to 9.5)
PrimaryNumber of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoids

A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 IU/mL.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoids
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-D235245228
Anti-T264266268
PrimaryNumber of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoids

A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoids
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-D265268270
Anti-T266268272
PrimaryAnti-D and Anti-T Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.1 IU/mL.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Geometric mean · IU/mL
Anti-D and Anti-T Antibody Concentrations
IU/mLInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-D0.174 (0.162 to 0.187)0.189 (0.176 to 0.202)0.154 (0.142 to 0.166)
Anti-T0.455 (0.429 to 0.483)0.511 (0.482 to 0.542)0.38 (0.357 to 0.403)
PrimaryAnti-D and Anti-T Antibody Concentrations

Antibody concentrations were presented as GMCs for the seroprotection cut-off of ≥ 0.1 IU/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Geometric mean · IU/mL
Anti-D and Anti-T Antibody Concentrations
IU/mLInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-D1.341 (1.239 to 1.451)1.504 (1.377 to 1.643)1.227 (1.134 to 1.326)
Anti-T4.862 (4.614 to 5.124)4.927 (4.693 to 5.173)4.371 (4.161 to 4.591)
PrimaryNumber of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)

A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentration ≥ 0.15 µg/mL.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)221229234
PrimaryNumber of Seroprotected Subjects Against PRP

A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentrations ≥ 0.15 µg/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against PRP
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Number of Seroprotected Subjects Against PRP264268271
PrimaryAnti-PRP Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 micrograms per milliliter (µg/mL).

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-PRP Antibody Concentrations2.308 (1.878 to 2.836)2.743 (2.245 to 3.352)2.407 (1.993 to 2.908)
PrimaryAnti-PRP Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 µg/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-PRP Antibody Concentrations35.178 (30.617 to 40.418)49.023 (43.649 to 55.058)27.682 (24.251 to 31.598)
PrimaryNumber of Seroprotected Subjects for Anti-polio Type 1, 2 and 3

A seroprotected subject was defined as a vaccinated subject with anti-polivirus antibody concentration ≥ 8 ED50. ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects for Anti-polio Type 1, 2 and 3
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-Polio 1253262263
Anti-Polio 2243256244
Anti-Polio 3249254250
PrimaryNumber of Seroprotected Subjects Against Polio Type 1, 2 and 3

A seroprotected subject was defined as a vaccinated subject with anti-polivirus antibody concentrations ≥ 8 ED50. ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Polio Type 1, 2 and 3
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-Polio 1265268273
Anti-Polio 2265268273
Anti-Polio 3265268273
PrimaryAnti-polio Type 1, 2 and 3 Antibody Titers

Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ the value of 8.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Geometric mean · Titers
Anti-polio Type 1, 2 and 3 Antibody Titers
TitersInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-Polio 172 (62 to 83.7)96.3 (82.8 to 112)75.9 (65.7 to 87.6)
Anti-Polio 256.5 (46.2 to 69)64.1 (53.8 to 76.4)41.9 (35 to 50)
Anti-Polio 372.6 (61.1 to 86.3)79.4 (65.8 to 95.8)60.3 (50.8 to 71.6)
PrimaryAnti-polio Type 1, 2 and 3 Antibody Titers

Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ 8.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Geometric mean · Titers
Anti-polio Type 1, 2 and 3 Antibody Titers
TitersInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-Polio 13512.2 (3159.7 to 3904.1)3410.9 (3081.7 to 3775.4)3386.8 (3078 to 3726.6)
Anti-Polio 21931.2 (1721.7 to 2166.2)2237.9 (2001.6 to 2502.1)1886.1 (1679.6 to 2117.9)
Anti-Polio 35237.8 (4671.8 to 5872.3)5438.5 (4846.8 to 6102.4)5141.2 (4650.1 to 5684.2)
PrimaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN

A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 ELISA units per milliliter (EL.U/mL).

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-PT254258253
Anti-FHA256262255
Anti-PRN254260260
PrimaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN

A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-PT266268273
Anti-FHA266268273
Anti-PRN266268273
PrimaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off value of ≥ 5 EL.U/mL.

Time frame:
Before the booster vaccination (At Day 0)
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
EL.U/mLInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-PT10.3 (9.5 to 11.1)12.2 (11.3 to 13.1)10.3 (9.5 to 11.2)
Anti-FHA12.7 (11.8 to 13.6)14.3 (13.4 to 15.2)12.3 (11.4 to 13.3)
Anti-PRN9.2 (8.7 to 9.6)9.7 (9.2 to 10.2)9 (8.5 to 9.5)
PrimaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrattions

Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrattions
EL.U/mLInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-PT138.5 (132 to 145.3)146.2 (139.7 to 153)126.8 (120.4 to 133.5)
Anti-FHA124.6 (119.2 to 130.2)124 (119.2 to 129)120.8 (115.3 to 126.6)
Anti-PRN57.3 (55.6 to 59.1)59.9 (58.1 to 61.8)57.2 (55.3 to 59.1)
PrimaryNumber of Subjects With a Booster Response to Anti-PT, Anti-FHA and Anti-PRN

Booster response was defined as the appearance of antibodies in subjects who were initially seronegative (i.e. with concentrations \< cut-off value) or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e. with concentrations ≥ cut-off value), taking into consideration the decreasing maternal antibodies.

Time frame:
One month after the booster vaccination (At Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With a Booster Response to Anti-PT, Anti-FHA and Anti-PRN
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Anti-PT266268272
Anti-FHA266268272
Anti-PRN239230244
SecondaryNumber of Subjects With Any Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
During the 4-day (Days 0-3) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited Local Symptoms
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Any Pain737476
Any Redness191519
Any Swelling161014
SecondaryNumber of Subjects With Any Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever \[defined as axillary temperature equal to or above 37.1 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade and relationship to vaccination.

Time frame:
During the 4-day (Days 0-3) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited General Symptoms
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Any Drowsiness385038
Any Irritability788172
Any Loss of appetite677369
Any Fever10210591
SecondaryNumber of Subjects With Any Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During the 31-day (Days 0-30) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited Adverse Events (AEs)
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Number of Subjects With Any Unsolicited Adverse Events (AEs)161321
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
During the entire study period (from Month 0 up to Month 1)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Number of Subjects With Serious Adverse Events (SAEs)100

Adverse events

Collected over Solicited local and general symptoms: during the 4-day (Days 0-3) post-vaccination period. AEs: within the 31-day (Days 0-30) period following booster vaccination. SAEs: throughout the entire study period (from Month 0 up to Month 1).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infanrix+Hib/Poliorix 1 Group0/272 (0%)1/272 (0.4%)157/272 (57.7%)
Infanrix+Hib/Poliorix 2 Group0/273 (0%)0/273 (0%)164/273 (60.1%)
Control Group0/280 (0%)0/280 (0%)158/280 (56.4%)
Most frequent serious events
Most frequent serious events
EventInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
Febrile convulsionNervous system disorders1/2720/2730/280
BronchopneumoniaInfections and infestations1/2720/2730/280
Most frequent other events
Most frequent other events
EventInfanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl Group
FeverGeneral disorders102/270105/27391/279
IrritabilityGeneral disorders78/27081/27372/279
PainGeneral disorders73/27074/27376/279
Loss of appetiteGeneral disorders67/27073/27369/279
DrowsinessGeneral disorders38/27050/27338/279
RednessGeneral disorders19/27015/27316/279
SwellingGeneral disorders16/27010/27314/279

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Infanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl GroupTotal
Mean19.5 ± 0.9319.4 ± 0.9119.5 ± 0.9719.47 ± 0.94
Sex: Female, Male
Sex: Female, Male(Participants)Infanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl GroupTotal
Female131126120377
Male141147160448
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Infanrix+Hib/Poliorix 1 GroupInfanrix+Hib/Poliorix 2 GroupControl GroupTotal
Asian-Chinese heritage272273280825
08

Study locations

2 sites
  • GSK Investigational Site
    Wuzhou, Guangxi 543002, China
  • GSK Investigational Site
    Wuzhou, Guangxi 543100, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 5 years 2 months after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2011
First posted
Oct 10, 2011
Start
Oct 1, 2011
Primary completionActual
Jan 16, 2012
CompletionActual
Jan 16, 2012
Results delay requested
Jul 24, 2012
Results first posted
Apr 13, 2017
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01449812
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 10, 2011
Start date
Oct 1, 2011
Primary completion
Jan 16, 2012
Completion
Jan 16, 2012
Results posted
Apr 13, 2017
Last update
Jun 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poliovirus Vaccine, Inactivated

Start the discussion